Aspen Aerogels (ASPN) Prices 4.25M Share Offering at $20/sh

Aspen Aerogels, Inc. (NYSE: ASPN) ("Aspen" or the "Company"), a technology leader in sustainability and electrification solutions, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of $20.00 per share. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 637,500 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Aspen from this offering are expected to be approximately $85 million, before deducting underwriting discounts and commissions and estimated offering expenses, and excluding any exercise of the underwriters' option to purchase additional shares of common stock. The offering is expected to close on October 23, 2024, subject to customary closing conditions.

Aspen intends to use the net proceeds from the offering for working capital, capital expenditures and general corporate purposes.

Goldman Sachs & Co. LLC and Morgan Stanley are acting as joint book-running managers for the offering.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (No. 333-282751), which was filed with the Securities and Exchange Commission (the "SEC") on October 21, 2024 and became effective upon filing. The offering will be made only by means of a written prospectus supplement and the accompanying prospectus that form part of the registration statement. A preliminary prospectus supplement relating to the offering and accompanying prospectus was filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to these securities, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at [email protected]; or Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities referred to in this press release, nor will there be any sale of any such securities, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

You May Also Be Interested In

• Manulife prices $750M subordinated notes offering at 6.146%
• Valion Bio names CFO Lisa Wolf as president and COO after CEO exits
• Tencent Music plans senior unsecured notes offering